Universal Cells is leveraging its Universal Donor Cell platform to treat diseases in a number of indications internally or with partners. The company is currently advancing the development of Universal Donor Cell-based therapies for undisclosed indications, and is developing Universal Donor T cells and Retinal Pigmented Epithelial Cells with partners.
Universal Cells is focused on strategic partnerships to accelerate development and extend market opportunities. We partner with academic and commercial entities.
In 2015, Universal Cells entered into a collaboration and exclusive license agreement with Adaptimmune, a leader in T-cell therapy to treat cancer, for the development of universal allogeneic T-cell therapies. With Universal Cells’ proprietary gene editing technology, Adaptimmune intends to develop affinity enhanced donor T-cells that are universally applicable. The enhanced T-cell technology involves selective engineering of cell surface proteins (TCRs and class I and class II HLA proteins), without the use of nucleases, to develop universal T-cell products.
In 2016, Universal Cells entered into a collaborative research and exclusive option agreement to create therapeutic off-the-shelf iPSCs with HEALIOS K.K. The partnership will focus on the production of Universal Donor iPSCs by editing the genes required for antigen presentation. During the option period, Universal Cells will engineer HEALIOS’ clinical-grade iPSCs. The exclusive option is for the treatment of dry/wet AMD, and for use with HEALIOS’ proprietary Organ Bud technology in liver and kidney clinical fields.
For discussion of our licensing opportunities or collaboration interests, please contact email@example.com